Treatment Algorithms: Colon Cancer | Market Research

The colon cancer pipeline has grown as pharmaceutical companies are attracted by the high incidence and success of other developers. Cytotoxics will remain an integral part of treatment, but with key brands expected to come off patent over the forecast period and the approval of new therapies, treatment of this growing market is set to evolve.

Features and benefits

• Disease overview assessing, etiology, risk factors, screening procedures, and patient segmentation
• In-depth analysis of most common treatment types according to stage at diagnosis and patient characteristics
• Analysis of physician prescribing trends in the seven major markets across all stages of disease
• Analysis of possible future treatment trends with regard to targeted therapies and companion diagnostics

Highlights

The standard of care for Stage I–III colon cancer is based around surgical resection. Advanced Stage II and Stage III tumors often require additional therapy in combination with surgery. FOLFOX accounts for 50% of the Stage IIIb market and is the preferred adjuvant chemotherapy regimen in all major pharmaceutical markets, except the UK.

First-line treatment of metastatic colon cancer is based on chemotherapy. Bevacizumab plus FOLFOX remains the most prescribed first-line regimen in less cost-conservative markets. However, in almost all pharmaceutical markets FOLFOX remains the chemotherapy of choice over FOLFIRI despite similar clinical efficacy in the metastatic setting.

Datamonitor’s survey indicated that the use of targeted therapies in the first- and second-line settings will increase. Increasing pressure to demonstrate cost-effectiveness of drugs and anticipated approval of new targeted therapies means the use of companion diagnostics will play an increasingly important role in the treatment of colon cancer.

Your key questions answered

• Gain insight into the treatment strategies and prescribing trends of 126 physicians treating colon cancer across the seven major markets
• Excel deliverable contains extensive treatment trees for each disease stage and country, including percentages and patient numbers
• Assess colon cancer market potential by identifying where treatment options are not fulfilling patient needs and how physicians select drugs